Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00089856
Other study ID # G-0029
Secondary ID (VITAL-1)
Status Terminated
Phase Phase 3
First received August 16, 2004
Last updated November 3, 2008
Start date July 2004
Est. completion date October 2008

Study information

Verified date November 2008
Source Cell Genesys
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the duration of survival between GVAX® immunotherapy for prostate cancer and chemotherapy treatment in patients with prostate cancer who no longer respond to hormone therapy, who have documented metastases, and who have not been treated with chemotherapy in the past.


Recruitment information / eligibility

Status Terminated
Enrollment 626
Est. completion date October 2008
Est. primary completion date October 2008
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Confirmed diagnosis of or clinical history consistent with adenocarcinoma of the prostate

- Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy

- Detectable metastases

- Any Gleason score

- ECOG performance status 0-2

Exclusion Criteria:

- Prior treatment with chemotherapy

- Prior Immunotherapy

- Prior treatment with gene therapy

- Significant cancer related pain

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Biological:
Immunotherapy with allogeneic prostate vaccine
Immunotherapy with allogeneic prostate vaccine
Drug:
Chemotherapy (Taxotere and prednisone)
Chemotherapy (Taxotere and prednisone)

Locations

Country Name City State
Belgium ZNA Middelheim Antwerp
Belgium Imelda Ziekenhuis Bonheiden
Belgium University Hospital Antwerp (UZA) Edegem
Belgium Unversity Hospial Gent Gent
Belgium UZ Gent Gent
Belgium Virga Jesse Ziekenhuis Hasselt
Belgium AZ Groeninge Kortrijk
Belgium Heilig Hartziekenhuis Roeselare Men Roeselare
Belgium Regionaal Ziekenhuis Sint Trudo Sint-Truiden
Canada CHUM Notre-Dam Montreal Quebec
Canada McGill University Montreal Quebec
Canada Ultra Med Inc. Pointe-Claire Quebec
Canada Centre Hopitalier Universitaire de Sherbrooke Sherbrooke Quebec
Canada Princess Margaret Hospital Toronto Ontario
France Centre Paul Papin Angers Cedex
France Centre Francois Baclesse Caen Cedex 5
France Centre Georges Francois Leclerc Dijon Cedex
France Centre Leon Berard Service de Cancerologie Medicale Lyon Cedex
France Institut Paoli-Calmettes Marseille
France Centre Rene Gauducheau Nantes-Saint Herblain
France Institut Jean Godinot Reims Cedex
France Centre Alexis Vautrin Vandoeuvre les Nancy Cedex
Germany Universitatsklinikum Aachen Urologie Aachen
Germany der Technischen Universitat Dresden Dresden
Germany Universitatsklinik um Essen Essen
Germany Universitatsklinik um des Saarlande Homburg/Saar
Netherlands VU Medisch Centrum Amsterdam
Netherlands University Medical Centre Groningen Groningen
Sweden University Hospital, Linkoping Linkoping
Sweden University Hospital Lund Lund
Sweden Akademiska University Hospital Uppsala
United Kingdom Addenbrooke's Hospital Cambridge
United Kingdom Beatson Oncology Centre Glasgow
United Kingdom St. James's University Hospital Leeds
United Kingdom Hammersmith Hospital London
United Kingdom Mount Vernon Hospital Middlesex
United Kingdom Newcastle General Hospital Newcastle upon Tyne
United Kingdom Northampton General Hosptial Northampton
United Kingdom Nottingham City Hospital Nottingham
United Kingdom Oxford Cancer Centre, Churchill Hospital Oxford
United Kingdom Scunthorpe General Hospital Scunthorpe
United Kingdom Royal Hallamshire Hospital Sheffield
United Kingdom Glan Clwyd Hospital Wales
United States Central Alabama Oncology, LLC Alabaster Alabama
United States The Don and Sybil Harrington Cancer Center Amarillo Texas
United States Alaska Clinical Research Center Anchorage Alaska
United States Atlanta VAMC Atlanta Georgia
United States Georgia Cancer Specialists Atlanta Georgia
United States Peachtree Hematology Oncology Consultants, PC Atlanta Georgia
United States Winship Cancer Institute, Emory University Atlanta Georgia
United States Univ. of Colorado Health Science Center Aurora Colorado
United States Urologic Surgery PC Bala Cynwyd Pennsylvania
United States Johns Hopkins University Baltimore Maryland
United States Southwestern Oncology Research Department Bennington Vermont
United States Deaconess Billings Clinic Billings Montana
United States Hematology/Oncology Centers of the Northern Rockies, P.C. Billings Montana
United States Medcenter One Cancer Care / Odyssey Research Bismarck North Dakota
United States Boca Raton Community Hospital, Inc. Boca Raton Florida
United States The Hope Clinic Bristol Connecticut
United States Jacobi Medical Center Bronx New York
United States Gabrail Cancer Center Canton Ohio
United States Charleston Hematology Oncology Charleston South Carolina
United States Presbyterian Hospital/ Center for Cancer Research Charlotte North Carolina
United States Memorial Health Care System Chattanooga Tennessee
United States The Center for Cancer & Hematologic Disease Cherry Hill New Jersey
United States University of Illinois at Chicago Chicago Illinois
United States Cleveland Clinic Foundation, Taussig Cancer Center Cleveland Ohio
United States Cancer Center of Colorado Springs Colorado Springs Colorado
United States Compassionate Cancer Care Medical Group, Inc. Corona California
United States Center for Oncology Research and Treatment PA Dallas Texas
United States Mary Crowley Medical Research Center Dallas Texas
United States Urology Specialists and Associates, P.A. Dallas Texas
United States Welborn Clinic Research Center Evansville Indiana
United States Dakota Cancer Institute Fargo North Dakota
United States Michael and Dianne Bienes Comprehensive Cancer Center, Holy Cross Hospital Fort Lauderdale Florida
United States Fort Wayne Medical Oncology/Hematology Inc. Fort Wayne Indiana
United States Pacific Coast Hem Onc. Medical Group Fountain Valley California
United States Frederick Memorial Hospital Regional Cancer Therapy Center Frederick Maryland
United States West Michigan Regional Cancer and Blood Center Free Soil Michigan
United States Palo Verde Hematology/Oncology Glendale Arizona
United States California Cancer Care Greenbrae California
United States Northwestern Carolina Hematology Oncology, PA Hickory North Carolina
United States Straub Clinic & Hospital Honolulu Hawaii
United States Mobley Research Center Houston Texas
United States Integrated Community Oncology Network Jacksonville Florida
United States Medical Oncology Associates Kingston Pennsylvania
United States Center for Urological Research La Mesa California
United States Louisiana Oncology Associates Lafayette Louisiana
United States Lancaster Cancer Center, Ltd Lancaster Pennsylvania
United States Urological Associates of Lancaster Lancaster Pennsylvania
United States Dartmouth-Hitchcock Medical Center Lebanon New Hampshire
United States Arkansas Cancer Research Center Little Rock Arkansas
United States Central Georgia Cancer Care, P.C. Macon Georgia
United States The West Clinic Memphis Tennessee
United States Oncology-Hematology Group of South Florida/Advanced Medical Specialists Miami Florida
United States Oncology Care Medical Associates Montebello California
United States Hematology-Oncology Associates of Northern New Jersey Morristown New Jersey
United States Urology Center of Grove Hill New Britain Connecticut
United States Columbia University Medical Center New York New York
United States Virginia Oncology Associates Norfolk Virginia
United States Cancer Centers of Florida Ocoee Florida
United States University of Oklahoma Oklahoma City Oklahoma
United States Omaha VA Medical Center Omaha Nebraska
United States Omaha VA Medical Center Omaha Nebraska
United States UC Irvine Medical Center Orange California
United States University of Pittsburgh Cancer Center Pittsburgh Pennsylvania
United States Hematology Oncology Associates of the Treasure Coast Port St. Lucie Florida
United States Providence Portland Medical Center Portland Oregon
United States William Beaumont Hospital, Cancer Clinical Trials Office Royal Oak Michigan
United States Urology Consultants Safety Harbor Florida
United States Urology San Antonio San Antonio Texas
United States San Bernardino Urological Associates San Bernardino California
United States Sharp Healthcare San Diego California
United States California Pacific Medical Center San Francisco California
United States Mayo Clinic Scottsdale Scottsdale Arizona
United States Seattle Cancer Care Alliance Seattle Washington
United States Virginia Mason Medical Center Urology Seattle Washington
United States Cancer Research & Prevention Center Soquel California
United States Newland Medical Associates, P.C. Southfield Michigan
United States Hematology Oncology Consultants, Inc. St. Louis Missouri
United States Carl & Dorothy Bennett Cancer Center Stamford Connecticut
United States Summit Medical Group/Overlook Oncology Center Summit New Jersey
United States SUNY Upstate Medical University Syracuse New York
United States ACRC/Arizona Clinical Res. Ctr. Inc. Tuscon Arizona
United States Tyler Cancer Center Tyler Texas
United States San Diego Cancer Center Vista California

Sponsors (1)

Lead Sponsor Collaborator
Cell Genesys

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  France,  Germany,  Netherlands,  Sweden,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Survival 0 No
Secondary Bone pain and bone related events 0 No
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A